NCT05058560 2025-03-13
Tislelizumab in Addition to BACE in Patients with NSCLC
The First Affiliated Hospital of Zhengzhou University
Phase 2 Completed
The First Affiliated Hospital of Zhengzhou University
Zhejiang Cancer Hospital
InventisBio Co., Ltd
University Hospital, Essen
Xinqiao Hospital of Chongqing
Xinqiao Hospital of Chongqing
TYK Medicines, Inc
Shanghai Junshi Bioscience Co., Ltd.
Beta Pharma, Inc.
IO Biotech
Asan Medical Center
Chinese University of Hong Kong
Hutchmed
Hutchmed
The Netherlands Cancer Institute
HiberCell, Inc.
Pierre Fabre Medicament
AstraZeneca
Fudan University
GlobeImmune
Intergroupe Francophone de Cancerologie Thoracique
Astellas Pharma Inc